Literature DB >> 7788146

Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome.

D Boumba1, F N Skopouli, H M Moutsopoulos.   

Abstract

The pattern of cytokine mRNA expression in frozen minor salivary gland tissues from patients with primary Sjögren's syndrome (pSS) (n = 12) and controls (n = 8) using an in situ hybridization technique and oligonucleotide probes of interleukin-1 beta (IL-1 beta), tumour necrosis factor alpha and beta (TNF-alpha and TNF-beta), interleukin-6 (IL-6), interleukin-2 (IL-2) and its receptor (IL-2R), interleukin-4 (IL-4), interleukin-10 (IL-10), interferon-gamma (IFN-gamma) and transforming growth factor-beta (TGF-beta) was examined. In addition to in situ hybridization, immunohistochemistry was used to identify the subset of cells expressing IL-2 and IL-4 mRNA. Mononuclear cells involved in the minor salivary gland lesions of pSS patients were found to express mRNA for pro-inflammatory cytokines such as TNF-alpha and IL-1 beta, and cytokines involved in the regulation of B- and T-cell function (IL-2 and IL-6). In contrast, only three biopsies from patients with pSS express mRNA of inhibitory cytokines such as IFN-gamma and TGF-beta. Furthermore mRNA for IL-6 and IL-1 beta was also detected in the glandular epithelial cells suggesting that these cells may play a role in the pathogenesis of autoimmune lesion in Sjögren's syndrome. IL-10 mRNA was not detected while IL-4 mRNA was primarily detected in naïve T-lymphocytes of patients with a mild and early lesion. These results suggest that local production of cytokines by both mononuclear and epithelial cells may be involved in the immune-mediated destruction of exocrine glands in patients with pSS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7788146     DOI: 10.1093/rheumatology/34.4.326

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  40 in total

Review 1.  Immunopathogenesis of Sjögren's syndrome.

Authors:  Andrea T Borchers; Stanley M Naguwa; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

2.  The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome.

Authors:  D I Mitsias; A G Tzioufas; C Veiopoulou; E Zintzaras; I K Tassios; O Kogopoulou; H M Moutsopoulos; G Thyphronitis
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

3.  Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjögren syndrome.

Authors:  Juan Wang; Huiyong Peng; Jie Tian; Jie Ma; Xinyi Tang; Ke Rui; Xinyu Tian; Yungang Wang; Jianguo Chen; Liwei Lu; Huaxi Xu; Shengjun Wang
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

Review 4.  Current status of gene delivery and gene therapy in lacrimal gland using viral vectors.

Authors:  Shivaram Selvam; Padmaja B Thomas; Sarah F Hamm-Alvarez; Joel E Schechter; Douglas Stevenson; Austin K Mircheff; Melvin D Trousdale
Journal:  Adv Drug Deliv Rev       Date:  2006-09-15       Impact factor: 15.470

5.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.

Authors:  Clio P Mavragani; Timothy B Niewold; Niki M Moutsopoulos; Stanley R Pillemer; Sharon M Wahl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2007-12

Review 6.  A conspicuous role for B cells In Sjögren's syndrome.

Authors:  Pierre Youinou; Valérie Devauchelle; Pascal Hutin; Rozenn Le Berre; Alain Saraux; Jacques-Olivier Pers
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 7.  Conventional therapy of Sjogren's syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 8.  The role of epithelial cells in the pathogenesis of Sjögren's syndrome.

Authors:  Menelaos N Manoussakis; Efstathia K Kapsogeorgou
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 9.  Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.

Authors:  Michael Voulgarelis; Fotini N Skopouli
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

10.  A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome.

Authors:  Hao Guo; Changrim Lee; Mihir Shah; Srikanth R Janga; Maria C Edman; Wannita Klinngam; Sarah F Hamm-Alvarez; J Andrew MacKay
Journal:  J Control Release       Date:  2018-10-23       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.